Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Adenosine Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.73 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.73 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.73 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.73 |
| ▸ | P2RY1 | P47900 | 11/20 | 0.77 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.77 |
| ▸ | SRC | P12931 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.77 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.77 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.77 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.73 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Triphosphate SCHEMBL3840392 | 1.00 | P2RY1 (0.77) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL28357 | 0.99 | P2RY1 (0.78) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL3040412 | 0.97 | P2RY1 (0.78) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL30936667 | 0.96 | P2RY1 (0.76) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL11579601 | 0.96 | P2RY1 (0.76) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL29803182 | 0.96 | P2RY1 (0.76) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL29723933 | 0.95 | P2RY1 (0.78) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Diphosphate SCHEMBL4734035 | 0.95 | P2RY1 (0.78) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL29636841 | 0.94 | P2RY1 (0.81) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Triphosphate SCHEMBL29392565 | 0.94 | P2RY1 (0.81) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533376-B2 | Prophylactic or therapeutic agent for disease induced by oxidative stress | OSAKA UNIVERSITY (JP) | 2026-01-27 | — | — | US | disclosed |
| US-11634545-B2 | Layered-substance-containing solution and method of manufacturing same | ADEKA CORPORATION (JP) | 2023-04-25 | — | — | US | disclosed |
| CN-115835871-A | Amorphous calcium carbonate for treating acidosis | 阿莫菲克公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114948992-A | Amorphous calcium carbonate for the treatment of leukemia | 艾玛菲克有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20210205172-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | REGIMEN KIT INC (JP) | 2021-07-08 | — | — | US | disclosed |
| US-11045510-B2 | Combination of aqueous extracts of watercress and nasturtium and ATP for use in the treatment of alopecia | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2021-06-29 | — | — | US | disclosed |
| EP-3838246-A1 | DRUG MANAGEMENT METHOD FOR KIT FORMULATION REQUIRING DOSE ADJUSTMENT | Regimen Kit, Inc. (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-20210145865-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASE INDUCED BY OXIDATIVE STRESS | OSAKA UNIVERSITY (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-3804732-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASE INDUCED BY OXIDATIVE STRESS | Osaka University (JP) | 2021-04-14 | — | — | EP | disclosed |
| US-20200085896-A1 | COMBINATION OF AQUEOUS EXTRACTS OF WATERCRESS AND NASTURTIUM AND ATP FOR USE IN THE TREATMENT OF ALOPECIA | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2020-03-19 | — | — | US | disclosed |
| CN-110088209-A | Bedded substance contains liquid and its manufacturing method | 株式会社ADEKA | 2019-08-02 | — | — | CN | disclosed |
| EP-3023109-A1 | ORALLY DISINTEGRATING TABLET | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136091-A1 | Orally Disintegrating Tablet | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-20100159449-A1 | Continuous Assay Method for Measuring Receptor- and Ion Channel-Mediated Calcium Response and Subsequent Gene Expression | NOACELL SCIENCE CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7569558-B2 | Topical delivery of trace metals for skin care | BIODERM RESEARCH (US) | 2009-08-04 | — | — | US | disclosed |
| EP-2036986-A1 | CONTINUOUS ASSAY METHOD FOR MEASURING RECEPTOR- AND ION CHANNEL-MEDIATED CALCIUM RESPONSE AND SUBSEQUENT GENE EXPRESSION | Noacell Science Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20060183708-A1 | Topical Delivery of Trace Metals for Enzyme Modulation | BIODERM RESEARCH (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006023710-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE | INFINITY2 HEALTH SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20040105894-A1 | Trace Metals synergized copper nucleotides and copper glycosides for anti-aging and antiviral compositions | GUPTA SHYAM K (US) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533376-B2 | Prophylactic or therapeutic agent for disease induced by oxidative stress | LPO, SI, TNF | ADRB2 3396/4885ADORA1 3867/4885PDE4D 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.